You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 201 Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Checkpoint blockade therapy
201 Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 202098024
Dec 20202206
Jan 20217407
Feb 2021111018
Mar 2021224018
Apr 2021219018
May 202191033
Jun 20210036
Jul 20210035
Aug 20210051
Sep 20210055
Oct 2021278052
Nov 2021228033
Dec 2021186020
Jan 2022198027
Feb 2022214021
Mar 2022260036
Apr 2022288030
May 2022294029
Jun 2022254021
Jul 2022226015
Aug 2022328018
Sep 2022324037
Oct 2022256017
Nov 2022196012
Dec 2022202014
Jan 2023192013
Feb 2023152012
Mar 202314205
Apr 2023138017
May 2023140011
Jun 2023210010
Jul 202314804
Aug 2023152014
Sep 202311806
Oct 2023180018
Nov 2023192012
Dec 202317809
Jan 202412604
Feb 202413005
Mar 2024172014
Apr 202416609
May 202413805
Jun 202415401
Jul 202413005
Aug 20247806
Sep 202418608
Oct 2024184012
Nov 202415402
Dec 202417607
Jan 20256208
Feb 20252401
Mar 2025002
Apr 2025009
May 2025003
Jun 2025003
Total83930918